Study on Digital Psychosocial Screening for Cancer Survivors Launched
A new study is assessing the feasibility of a digital psychosocial screening for cancer survivors to improve care access.
Phase III
cancer survivors
Status
Initiated
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
Pharma companies should consider integrating psychosocial support into their patient care strategies to enhance treatment adherence and outcomes.
Why it matters
The launch of a study on digital psychosocial screening for cancer survivors highlights a growing emphasis on holistic patient care in oncology. This could reshape competitive dynamics as pharma companies may need to adapt their strategies to include psychosocial support to improve treatment adherence and patient outcomes.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor results on feasibility and acceptability of the screening process and its impact on patient outcomes.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.